LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) concerning possible violations of federal securities laws.
On February 23, 2017, pre-market, Boston Scientific announced a voluntary recall of its range of Lotus Valve heart devices, citing reports of an early release of a pin that attaches the heart valve device to the delivery system.
Boston Scientific claims the problem is created by "excess tension in the pin mechanism introduced during the manufacturing process." When this information was announced to the investing public, the value of Boston Scientific declined, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.